Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care [0.03%]
数字治疗的潜力：药物汇编中纳入经管护理的一致性和细化的需求分析
Ann Johnson,Rick Bartels,Joe Honcz et al.
Ann Johnson et al.
The field of digital therapeutics (DTx), software programs that prevent, manage, and treat medical conditions, continues to grow. DTx offers new treatment options and has the potential to close gaps in care caused by unmet patient needs, pr...
AMCP Partnership Forum: Patient input and payer decision-making [0.03%]
AMSUS会议演讲：从患者的角度思考支付方的决策制定过程
There has been growing consensus for the health care community to become more patient centered by considering patient needs, preferences, and values in decision-making. To advance partnership between payers and patient representatives to ga...
A descriptive survey of patient experiences and access to specialty medicines with alternative funding programs [0.03%]
关于患者经历和利用替代性资金渠道获取专科药物的描述性调查报告
William B Wong,Irina Yermilov,Hannah Dalglish et al.
William B Wong et al.
Background: Alternative funding programs (AFPs) seek to reduce health plan sponsor costs, for example by excluding specialty drugs from a beneficiary's plan coverage and requiring patients to obtain medications through al...
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement [0.03%]
多发性硬化患者报告的残疾进展结局：基于结果的协议研究结果
Elizabeth C S Swart,Samuel K Peasah,Jacqueline Alderson et al.
Elizabeth C S Swart et al.
Background: Outcomes-based agreements (OBAs) are agreements between payers and manufacturers in which payment for medications is tied to patient outcomes. These contracts aim to measure the value of prescription medicatio...
Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States [0.03%]
美国1型糖尿病患者共病抑郁和焦虑与卫生资源利用的关系
Yueh-Yi Chiang,Susan dosReis,Charmaine Rochester-Eyeguokan et al.
Yueh-Yi Chiang et al.
Background: Type 1 diabetes mellitus (T1DM) is a prevalent chronic endocrine disorder and accounts for 5%-10% of all diabetes cases worldwide. T1DM can have a substantial impact on health care utilization. Although it is ...
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States [0.03%]
美国中年多发性硬化患者的疾病修正疗法中断对医疗保健利用的影响
Yiran Qian,Carolyn T Thorpe,Casey Tak et al.
Yiran Qian et al.
Background: Multiple sclerosis (MS) is a lifelong progressive neurological disease treated primarily with disease-modifying therapies (DMTs). Disease activity tends to decline as patients age. Midlife represents a crossro...
Health care resource utilization and costs across stages of amyotrophic lateral sclerosis in the United States [0.03%]
美国肌萎缩侧索硬化症不同阶段的卫生资源利用和成本状况
Katie Stenson,Sheena Chew,Shaobin Dong et al.
Katie Stenson et al.
Background: People living with ALS (plwALS) experience motor control loss, speech/swallowing difficulties, respiratory insufficiency, and early death. Advancing disease stage is typically associated with a greater burden ...
Potential benefits of incorporating social determinants of health screening on comprehensive medication management effectiveness [0.03%]
综合药物管理中纳入健康社会决定因素筛查的潜在益处
Joel F Farley,Swetha Pradeep
Joel F Farley
Background: Increasingly, pharmacists are asked to incorporate social determinants of health (SDoH) identification and referral into clinical practice. However, to date, no studies have evaluated clinical changes from emb...
The effectiveness and value of ensifentrine for the treatment of chronic obstructive pulmonary disease [0.03%]
恩西芬特林治疗慢性阻塞性肺疾病的疗效和价值
Abigail C Wright,Grace A Lin,Melanie D Whittington et al.
Abigail C Wright et al.
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study [0.03%]
ODESSA-CD研究：初治克罗恩病患者生物制剂递增剂量治疗效果分析
Noa Krugliak Cleveland,Sabyasachi Ghosh,Niranjan Kathe et al.
Noa Krugliak Cleveland et al.
Background: Dose escalation of biologics may restore response in patients with Crohn's disease (CD) who experience inadequate response or loss of response, but the rates of dose escalation and subsequent adverse clinical ...